Continuing the Story: AstraZeneca and Mindpeak GmbH present new real-world results on AI-assisted HER2 scoring at ASCO 2025Following our oral presentation last Friday on the AI-assisted training for HER2 IHC interpretation, we are proud to share insights on the Monday’s poster session that took place at this year American Society of Clinical Oncology (ASCO) Annual Meeting.This time, it’s about real-world diagnostics. In collaboration with six academic centers across the globe, we evaluated whether AI can truly enhance accuracy and consistency in daily pathology practice.And the answer is clear:AI support boosted diagnostic agreement among pathologists to 86.4% for HER2-low and by 15% to 80.6% for HER2-ultralow - a major leap in consensus for some of the most challenging scoring decisions.Misclassification of HER2-null cases dropped by 64.5%, meaning more patients who may benefit from novel therapies like Enhertu can now be correctly identified.Accuracy rose across the board, especially in the critical 0 vs. 1+ distinction - an area long known for variability and clinical impact.Together, the oral and poster presentations offer a comprehensive view of how AI can support reproducible, high-quality HER2 assessment at scale - from training to clinical practice.As the clinical importance of HER2-low and ultralow scoring continues to grow, our findings provide strong evidence that AI can play a pivotal role in expanding access to targeted therapies like Enhertu - by enabling greater diagnostic precision.
Continuing the Story: AstraZeneca and Mindpeak GmbH present new real-world results on AI-assisted HER2 scoring at ASCO 2025
Related reading
Mindpeak Expands to the United States with New Headquarters in Boston
We are proud to announce the official launch of Mindpeak Inc. in Boston, establishing our new US headquarters at the heart of the world’s leading pharma, biotech, and diagnostics ecosystem.
This milestone represents more than the opening of an office. It reflects our commitment to collaborating closely with innovators across the United States to:
- Accelerate biomarker discovery and companion diagnostics
- Advance the development of cancer therapies
- Enable faster, more precise matching of treatments to patients
With a permanent presence in the US, we are making advanced AI-powered pathology part of everyday workflows—providing reproducible, high-quality insights that transform complex data into better patient outcomes.
At Mindpeak, we look forward to building strong partnerships and shaping the future of precision medicine together.
Read the full article here
Mindpeak Featured in Ada Ventures’ Bio‑Infrastructure Spotlight
We’re excited to share that Mindpeak has been recognized by Ada Ventures as part of a select group of innovators building the next-generation infrastructure for global health.
In their recent spotlight, Ada Ventures highlights the urgency of rethinking healthcare systems to meet the demands of a longer-living, more complex global population. Their vision spans five critical pillars of bio‑infrastructure—from lab automation to talent development, with Mindpeak featured under "Patient Data Platforms" for our contributions to secure, inclusive, and actionable health data.
At Mindpeak, we’re proud to play a pivotal role in this transformation:
Advancing Precision Diagnostics
Our AI software brings cutting-edge biomarker translation directly into pathology workflows—supporting clinicians in identifying breast, lung, and other cancers with speed and precision.
Making Patient Data Clinically Useful
Unlike conventional data platforms, we focus on real-time, tissue-based insights that are immediately actionable in the clinic. This enables faster decision-making and more equitable access to personalized care.
Scaling Globally
With deployments across 20+ countries and partnerships with leading labs, we’re not just imagining the future, we’re delivering it, one slide at a time.
We’re honored to be included alongside visionary companies across the healthcare and life sciences ecosystem. Together, we’re helping build a world where AI, data, and infrastructure truly serve everyone.
🔗 Read Ada Ventures’ full bio‑infrastructure spotlight
Mindpeak GmbH featured at AlbionVC HLTH 2025
We’re thrilled that Mindpeak GmbH has been featured in the AlbionVC HLTH Europe HealthTech Market Map 2025, which includes leading companies across digital care and digital pharma in Europe!
Explore the European HealthTech landscape in AlbionVC’s interactive map: https://lnkd.in/da6H84sJ
Ready to advance your diagnostics
Connect with our team to explore how precision pathology works in your setting